Acute myeloid leukemia presenting with panhypopituitarism and diabetes insipidus

Fulya Akin1, Şenay Topsakal1, Veysel Erol 2, Guzin Fidan Yaylali1, Yılmaz Kiroglu3, Mehmet Sercan Erturk1

1Pamukkale University, Faculty of Medicine, Department of Endocrinology and Metabolism, Denizli, 20070, Turkey
2Pamukkale University, Faculty of Medicine, Department of Internal Medicine, Denizli, 20070, Turkey
3Pamukkale University, Faculty of Medicine, Department of Radiology, Denizli, 20070, Turkey

Introduction
Central nervous system involvement is rare in acute myeloid leukemia (AML) cases. Pituitary involvement is much more rarely seen with unknown frequency and if left untreated, may result in death. Although rarely seen, leukemic infiltration of the pituitary gland should be evaluated in leukaemic patients with visual disturbance, hypopituitarism or central diabetes insipidus (CDI). To date, AML presenting with CDI has been rarely reported. The presence of both anterior and posterior pituitary deficiency is even rarer with unknown prevalence. Here, we present a patient with AML (subtype classification is proceeding) presenting with panhypopituitarism and CDI.

Case report
A 37 years old man, with no significant past medical history, presented to emergency department with complaint of high fever, polyuria and polydipsia. Laboratory tests revealed increased CRP, ESR, serum sodium was 157 mEq/L. Patient diagnosed as panhypopituitarism according to the pituitary hormones values (TSH:0.04 ulU/ml, (0.2-4.2), fT4:0.801 ng/dL(0.99-1.65), kortizol:3.21 ug/dL, ACTH:12.3 pg/mL). On the cranial mri, FLAIR image shows hyperintense lesions in bilateral hypothalamic areas probable due to leukemic infiltration (image 1). Contrast-enhanced T1W-coronal image demonstrates rim enhancement pattern (image 2). mri spectroscopy reveals high ch/cho and cho/nac ratios (image 3-4). Patient admitted the endocrinology clinic and hyponatremic IV hydration (%60 saline and %5 dextroz) was given in order. After the initiation of this treatment, urine output was noticed to be 6000-7000 cc per day. Water deprivation test showed worsening of hyponatremia (sodium: 151 mEq/L), and serum osmolality test showed hyperosmolality (312 mOsm/kg) with inappropriate low urine osmolality (130 mOsm/kg). Urinary osmolality was increased by two times following vasopressin administration. Nasal 1-deamino-8-D-arginine vasopressin (DAVP) was started with the diagnosis of central diabetes insipidus. Polyuria and polydipsia were improved under DDAVP treatment and correction of hyponatremia and dehydration. Patient was treated with prednisolone, desmopressin and levotirothyroxine sodium for panhypopituitarism. On the third day of admission, the laboratory studies showed neutropenia (white blood cell 2.6 K/µL), macrocytic anaemia (Hemoglobin 10.2 g/dL, MCV 131.7 fl) and mild thrombocytopenia. Patient family history was noncontributory. The detailed history showed that the patient had unintentional weight loss of 20 pounds in the past 1 month. The physical examination showed pale conjunctivae. No other significant abnormality was noticed on examination. Examination of a peripheral blood smear revealed moderate normochromic normocytic anaemia with no rouleaux formation. Mild anisocytosis and occasional oval macrocytes were noted. The majority of nucleated blood cells were large with myeloid features with a few atypical blastic cells. The serum total protein was decreased at 52 g/L (reference range 85-85) and beta2-microglobulin elevated at 6.3 mg/L (reference range <2). Serum immunoglobulin levels were in normal range, with IgG:1306 mg/dl, lgA:170 mg/dl, IgM:214 mg/dl, kappa light chain:347, lambda light chain:205 mg/dl. A smear of bone marrow aspirate showed sheets of myeloid cells that accounted for 82% of the overall nucleated cell population. Large, binucleate and trinucleate forms were noted. Many of these atypical myeloid cells contained small, inconspicuous nucleioli. A diagnosis of myeloid leukemia was made by hematology. Patient will follow up hematology clinic for further investigation and treatments.

Discussion
CDI in patients with AML is uncommon with a prevalence of less than 1%. It may occur at the same time or after the diagnosis of hematological disease. CDI associated with AML may develop due to leukemic infiltration and different mechanisms such as chromosomal abnormality, dysmegakaryopoiesis and thrombocytopenia. Monosomy 7 is the most common cytogenetic chromosomal abnormality determined in these cases. It has been shown that the presence of DI and monosomy 7 was associated with higher mortality rates than DI without this abnormality. The other chromosomal abnormality is structural abnormalities on the long arm of chromosome 3. In genetic analyses, there was no chromosomal abnormality in our patient. Lavabre-Bertrand et al. described thrombocytosis in three patients with AML and DI, all showing monosomy 7 and chromosome 3 abnormalities. Interestingly, these three cases had a normal computed tomography scan of the brain. The authors stated that this might be a new disease entity. Although our patient had slightly elevated platelet count, there wasn’t pituitary involvement by leukemic cells on MRI like previous cases. When pituitary involvement detected, hormone function tests are required for both anterior and posterior lobes of the pituitary gland. Adrenal insufficiency and hypothyroidism may mask diabetes insipidus, thus, steroid and thyroid treatment can cause diabetes insipidus. We found only three cases of AML presenting with panhypopituitarism and DI in the literature. However, subtypes of AML were not stated in those reports except one case due to acute myelomonocytic leukemia.

References

Conclusions:
In conclusion, this is the rare case of reporting coexistence of AML, CDI, panhypopituitarism and hypothalamic lesions probable due to leukemic infiltration.